FDA clears new AI-powered 12-lead ECG from AliveCor

AliveCor has announced FDA clearance for its Kardia 12L, a groundbreaking handheld ECG system. The device employs a deep neural network machine learning AI model, KAI 12L AI, trained on over one million recorded ECGs to detect 35 different cardiac conditions, including myocardial infarction and common types of cardiac ischemia.

Weighing just 0.3 lbs, the battery-operated Kardia 12L uses a single cable with a reduced lead set and only five electrodes, as opposed to the standard ten. This reduction simplifies and expedites the process of obtaining high-quality ECG readings, allowing physicians to quickly detect cardiac diseases. The system's AI algorithms enable it to provide readings similar to those of a standard 12-lead ECG machine in diverse healthcare settings, including urgent care, doctor’s offices, and home healthcare.

AliveCor emphasizes that the FDA clearance will expand access to 12-lead ECG recording, particularly in under-resourced and rural areas, enhancing patient experiences and outcomes by streamlining care. The device requires minimal specialized training, potentially reducing the need for patient referrals and preventing delays in cardiac treatment. This development marks significant progress in cardiac care accessibility and efficiency.

Priya Abani, CEO of AliveCor, highlighted the system's innovation, noting its ability to detect a heart attack with a reduced lead set and its broad range of condition determinations. Abani stated that the pocket-sized Kardia 12L ECG system is poised to disrupt traditional care pathways and represents a significant leap forward in cardiac care. Recent data presented by AliveCor supports the system's accuracy, showing strong correlation with standard 12-lead ECG technology in clinical studies, thus confirming its efficacy for rapid and comprehensive ECG information acquisition.

Click here to read the original news story.